EBS vs. CLDX, INVA, DVAX, MNKD, NVAX, OPK, GERN, RGLS, MYGN, and ZBIO
Should you be buying Emergent Biosolutions stock or one of its competitors? The main competitors of Emergent Biosolutions include Celldex Therapeutics (CLDX), Innoviva (INVA), Dynavax Technologies (DVAX), MannKind (MNKD), Novavax (NVAX), OPKO Health (OPK), Geron (GERN), Regulus Therapeutics (RGLS), Myriad Genetics (MYGN), and Zenas BioPharma (ZBIO). These companies are all part of the "biotechnology" industry.
Emergent Biosolutions vs. Its Competitors
Celldex Therapeutics (NASDAQ:CLDX) and Emergent Biosolutions (NYSE:EBS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.
Celldex Therapeutics has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Comparatively, Emergent Biosolutions has a beta of 2.09, meaning that its stock price is 109% more volatile than the S&P 500.
Celldex Therapeutics currently has a consensus price target of $50.11, suggesting a potential upside of 128.04%. Emergent Biosolutions has a consensus price target of $14.33, suggesting a potential upside of 105.05%. Given Celldex Therapeutics' higher possible upside, equities analysts plainly believe Celldex Therapeutics is more favorable than Emergent Biosolutions.
Emergent Biosolutions has a net margin of -13.63% compared to Celldex Therapeutics' net margin of -2,366.07%. Emergent Biosolutions' return on equity of -0.52% beat Celldex Therapeutics' return on equity.
78.4% of Emergent Biosolutions shares are held by institutional investors. 4.4% of Celldex Therapeutics shares are held by company insiders. Comparatively, 1.2% of Emergent Biosolutions shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Celldex Therapeutics has higher earnings, but lower revenue than Emergent Biosolutions. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Emergent Biosolutions, indicating that it is currently the more affordable of the two stocks.
In the previous week, Emergent Biosolutions had 1 more articles in the media than Celldex Therapeutics. MarketBeat recorded 2 mentions for Emergent Biosolutions and 1 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 0.00 equaled Emergent Biosolutions'average media sentiment score.
Summary
Emergent Biosolutions beats Celldex Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Emergent Biosolutions News Delivered to You Automatically
Sign up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding EBS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Emergent Biosolutions Competitors List
Related Companies and Tools
This page (NYSE:EBS) was last updated on 7/4/2025 by MarketBeat.com Staff
